Oral Contraceptive Market Report 2025 (Global Edition)

Global Oral Contraceptive Market Report 2025 Market Size Split by Type (Combination, Progestin Only), by Application (Male, Female), by Types of Combination Pills (Monophasic, Biphasic, Triphasic, Qua...

Oral Contraceptive Market Report Description

We have various report editions of Oral Contraceptive Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Top Companies in Oral Contraceptive Market

The pharmaceutical and healthcare industry is highly competitive, with key players expanding their portfolios through new product launches, mergers and acquisitions, strategic partnerships, and regulatory approvals.

Financial performance metrics include revenue, gross margin, and market share, as well as SWOT analysis for key players. The report also evaluates companies' responses to COVID-19 challenges, including supply chain adjustments and investments in digital healthcare solutions.

The market size is projected based on global, regional, and country-level demand patterns, with research including value chain analysis, patent analysis, and competitive matrix. This comprehensive study serves as a vital resource for investors, industry stakeholders, and businesses navigating the evolving pharmaceutical and healthcare landscape.

Top Companies Market Share in Oral Contraceptive Industry: (In no particular order of Rank)

• Bayer
• Janssen Global Services
• Teva Pharmaceutical
• Merck
• Pfizer
• Mankind Pharma
• Actavis
• Syzygy Healthcare
• Lupin Pharmaceuticals
• Reckitt Benckiser.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which Region Dominates the Oral Contraceptive Market in 2024?

According to Cognitive Research, the North American region dominated the market and accounted for the highest revenue of XX% in 2024, and it is projected that it will grow at a CAGR of XX% in the future. This growth is supported by several factors, such as increasing awareness and education, growing demand for family planning, rising prevalence of hormonal disorders, women’s lifestyle changes, advancements in oral contraceptive pills, and government support and insurance coverage. For instance, In the U.S., the Affordable Care Act (ACA) mandates insurance coverage for birth control. https://www.hhs.gov/healthcare/about-the-aca/index.html
Additionally, in July 2023, the U.S. Food and Drug Administration approved Opill (norgestrel) tablets for non-prescription use to prevent pregnancy, the first daily oral contraceptive approved for use in the U.S. without a prescription. https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive. The approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores, and grocery stores, as well as online.  
Moreover, the advancements in the oral contraceptive market are increasing for instance, Advances in oral contraceptive formulations have led to extended cycle and continuous-use regimes. (84 and 365 days of active pills). https://pubmed.ncbi.nlm.nih.gov/20391327/ These options reduce the frequency of menstrual periods and associated symptoms, offering greater convenience and satisfaction for users, which further fuels the market growth. 
 

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific Region is expanding at the Fastest CAGR in the oral contraceptive market. In Asia, approximately 5.4% of women aged 15–44 years old get pregnant unintentionally, and the number of unintended pregnancies is 53.8 million each year in Asia, thus increasing the need for more oral contraception. In November 2023, The European Parliamentary Forum for Sexual and Reproductive Rights (EPF),?FP2030, and IPPF East & South East Asia and Oceania Region is pleased to announce the launch of the first Contraception Policy Atlas Asia and the Pacific https://www.epfweb.org/node/1033. This initiative aims to assess and enhance contraceptive policies across the region, promoting informed choices and easy access to oral contraception. 
Additionally, as of 2025, contraceptive pills such as Yaz and Yasmin have been added to Australia’s PBS, reducing costs for approximately 50,000 women annually. This move enhances the affordability and accessibility of modern portal contraceptives, reflecting a commitment to improve women's health. The Asia Pacific contraceptive market is expected to witness rapid growth driven by government initiatives aimed at population control and reducing unwanted pregnancies.

The current report Scope analyzes Oral Contraceptive Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

Oral Contraceptive Market Analysis

The dominant segment in the Oral contraceptive market is Combination Pills (Estrogen + Progestin) due to its Widespread use, regulatory approval, additional benefits, and brand familiarity. These pills have been on the market the longest and are the most commonly prescribed due to their effectiveness and cycle regulation benefits. Most healthcare providers recommend combination pills as a first-line contraceptive method. It has additional benefits and is often used to treat conditions like acne, PCOS, and menstrual disorders in addition to preventing pregnancy.
The fastest-growing segment is the Progestin-Only Pills (Mini Pills) due to its suitability for more users, Recent FDA approvals, growing demand for hormone-specific control, and increasing use post-partum and in older age groups. It is ideal for women who can't take estrogen due to risks like blood clots, smoking, or breastfeeding. In 2023, the FDA approved Opill (a progestin-only pill) as the first over-the-counter (OTC) oral contraceptive in the U.S., significantly boosting interest and accessibility. Additionally, consumers are more aware of hormonal sensitivities and side effect profiles, leading to demand for estrogen-free options.
 

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Oral Contraceptive Industry. Request a Free Sample PDF!

Application Segment Analysis of Oral Contraceptive Market

This report analyzes revenue growth in the pharma and healthcare industry at global, regional, and national levels, highlighting trends and opportunities for each application. It explores how sectors like pharmaceuticals, therapy, and healthcare monitoring use innovations to address healthcare needs. Key factors include market size, revenue contributions, technological advancements (e.g., AI-driven diagnostics), and regulatory considerations. The report also covers the value chain, identifying key players and processes within the industry. For more information, please request a sample or contact our research team.

Some of the key Application of Oral Contraceptive are:

• Male
• Female

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Oral Contraceptive Types of Combination Pills Segment Analysis

• Monophasic
• Biphasic
• Triphasic
• Quadriphasic

Oral Contraceptive Age Group Segment Analysis

• 15–24 years
• 25–34 years
• 35+ years

Oral Contraceptive Distribution Channel Segment Analysis

• Retail Pharmacies and drug stores
• Online retail
• Clinics and Hospitals
• Public channels
• NGO’s

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion